尿路上皮癌胚抗原1在卵巢癌组织中的表达及临床意义

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1202 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的: 研究上皮性卵巢癌(epithelial ovarian cancer，EOC)患者卵巢癌组织中长链非编码RNA尿路上皮癌胚抗原1(urothelial carcinoembryonic antigen 1，UCA1)的表达及临床意义。方法: 收集30例卵巢良性疾病者及66例EOC患者卵巢组织样本，应用实时定量PCR法检测UCA1表达。应用ROC曲线分析UCA1表达对卵巢癌的诊断意义，并以ROC方法将EOC患者分为UCA1高表达组和低表达组，分析两组临床病理参数间的差异；通过KaplanMeier生存分析评价UCA1表达对患者生存的影响。结果： EOC患者UCA1表达水平明显高于卵巢良性疾病者(P<0.05)。ROC曲线分析表明UCA1表达能够很好地区分EOC与卵巢良性疾病，曲线下面积为0.838(95%CI：0.749～0.927，P<0.05)。UCA1异常表达与FIGO分期、肿瘤分化程度以及淋巴结转移相关(P<0.05)。UCA1高表达者总体生存及无病生存明显低于UCA1低表达者(P=0.004，0.037)。结论： UCA1过表达是EOC患者的常见分子事件，可作为EOC患者预后不佳的分子标志。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：尿路上皮癌胚抗原1, 上皮性卵巢癌, 诊断, 预后

Abstract：Objective: To investigate the expression of long noncoding RNA urothelial carcinoembryonic antigen 1(UCA1) in patients with epithelial ovarian cancer(EOC) and its clinical significance. Methods: Ovarian tissue of 30 benign ovarian disease patients and 66 EOC patients were collected. UCA1 expression level was examined by realtime quantitative PCR. The diagnostic value of UCA1 expression was analyzed by ROC curve. The patients with EOC was divided into UCA1high and UCA1low expression group according to ROC method; and the clinicopathological parameters were analyzed. KaplanMeier analysis was used to determine the effect of UCA1 expression on survival time. Results: UCA1 expression of EOC patients was significantly upregulated than that of patients with benign ovarian disease(P<0.05). ROC analysis revealed UCA1 expression could distinguish EOC from benign ovarian disease with the AUC of 0.838(95%CI: 0.749-0.927, P<0.05). Abnormal expression of UCA1 was associated with FIGO stage, tumor differentiation and lymph node metastasis(P<0.05). Patients with highUCA1expression had a significantly shorter overall survival time and diseasefree survival time than patients with lowUCA1expression (P=0.004，0.037, respectively). Conclusion: Overexpression of UCA1 was observed in EOC, and it could be served as a poor prognostic biomarker in EOC.

收稿日期: 2017-08-14

作者简介: 谭歆（1985—），女，江苏镇江人，主治医师，硕士，主要从事妇科肿瘤疾病的研究。

引用本文:

谭歆. 尿路上皮癌胚抗原1在卵巢癌组织中的表达及临床意义[J]. 江苏大学学报:医学版, 2018, 28(01): 61-64. TAN Xin. Expression of urothelial carcinoembryonic antigen 1 in epithelial ovarian cancer and its clinical significance. Journal of Jiangsu University(Medicine Edition), 2018, 28(01): 61-64.

链接本文:

http://zzs.ujs.edu.cn/xbyxb/CN/ 或 http://zzs.ujs.edu.cn/xbyxb/CN/Y2018/V28/I01/61

1］Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012\[J\]. CA Cancer J Clin, 2015, 65(2): 87-108.
［2］Bast RC Jr, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation\[J\]. Nat Rev Cancer, 2009, 9(6): 415-428.
［3］Li C, Liang G, Yang S, et al. Dysregulated lncRNAUCA1 contributes to the progression of gastric cancer through regulation of the PI3KAktmTOR signaling pathway\[J\]. Oncotarget, 2017, 8（55）:93476-93491.
［4］Cai Q, Jin L, Wang S, et al. Long noncoding RNA UCA1 promotes gallbladder cancer progression by epigenetically repressing p21 and Ecadherin expression\[J\]. Oncotarget, 2017, 8(29):47957-47968.
［5］Li D, Li H, Yang Y, et al. Long noncoding RNA urothelial carcinoma associated 1 promotes the proliferation and metastasis of human lung tumor cells by regulating microRNA144\[J\]. Oncol Res, 2017. \[Epub ahead of print\].
［6］Yang Y, Jiang Y, Wan Y, et al. UCA1 functions as a competing endogenous RNA to suppress epithelial ovarian cancer metastasis\[J\]. Tumour Biol, 2016, 37(8): 10633-10641.
［7］Wang F, Zhou J, Xie X, et al. Involvement of SRPK1 in cisplatin resistance related to long noncoding RNA UCA1 in human ovarian cancer cells\[J\]. Neoplasma, 2015, 62(3):432-438.
［8］Xue M, Chen W, Li X. Urothelial cancer associated 1: a long noncoding RNA with a crucial role in cancer\[J\]. J Cancer Res Clin Oncol, 2016, 142(7): 1407-1419.
［9］He A, Hu R, Chen Z, et al. Role of long noncoding RNA UCA1 as a common molecular marker for lymph node metastasis and prognosis in various cancers: a metaanalysis\[J\]. Oncotarget, 2017, 8(1):1937-1943.
［10］Zhang L, Cao X, Zhang L, et al. UCA1 overexpression predicts clinical outcome of patients with ovarian cancer receiving adjuvant chemotherapy\[J\]. Cancer Chemother Pharmacol, 2016, 77(3):629-634.
［11］Wang H, Guan Z, He K, et al. LncRNA UCA1 in anticancer drug resistance\[J\]. Oncotarget, 2017, 8(28): 64638-64650.
［12］Jiao C, Song Z, Chen J, et al. lncRNAUCA1 enhances cell proliferation through functioning as a ceRNA of Sox4 in esophageal cancer\[J\]. Oncol Rep, 2016, 36(5): 2960-2966.
［13］Qian Y, Liu D, Cao S, et al. Upregulation of the long noncoding RNA UCA1 affects the proliferation, invasion, and survival of hypopharyngeal carcinoma\[J\]. Mol Cancer, 2017, 16(1):68.
［14］Wen JJ, Ma YD, Yang GS, et al. Analysis of circulating long noncoding RNA UCA1 as potential biomarkers for diagnosis and prognosis of osteosarcoma\[J\]. Eur Rev Med Pharmacol Sci, 2017, 21(3):498-503.